Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma

Sponsor
Qian Chu
Study ID
NCT04888429
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Sarcomatoid Carcinoma of Lung

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Camrelizumab — DRUG
    Patients received camrelizumab 200 mg every 3 weeks
  • Famitinib — DRUG
    Patients received Famitinib 20 mg once per day

Study Details

This is a single arm, multi-center clinical trial. Target population is patients with Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma，aiming to evaluate the efficacy and safety of the combination therapy of Camrelizumab and famitinib . Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody, and famitinib is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor.

Key Dates

Start date
Jul 19, 2021
Status verified
Sep 2024
Primary completion
Dec 30, 2024
Completion
Jun 30, 2025

Study Design

Enrollment
28 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Camrelizumab + Famitinib
    Patients received camrelizumab 200 mg every 3 weeks and famitinib 20 mg once per day.

Primary Outcome Measure

Objective Response Rate (ORR) [ Time Frame: about 24 month ]

Central Contacts